Predictors and Outcomes of Completion Axillary Node Dissection Among Older Breast Cancer Patients
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The role of completion axillary lymph node dissection (ALND) for older women who had sentinel lymph node-positive (SLN+) invasive breast cancer is unclear. We examined factors predictive of ALND and the association between ALND, adjuvant chemotherapy administration, and survival.
Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we reviewed records of women age >65 diagnosed with stage I/II breast cancer from 1998–2005. Adjusted Cox proportional hazards and multivariate logistic regression were used to identify patient and disease variables associated with ALND, and assess association between ALND and all-cause and breast cancer-specific survival.
Among SLN+ patients, 88 % underwent ALND. Earlier diagnosis year, greater nodal involvement, younger age, registry location, and larger tumor size were all associated with a significantly higher likelihood of ALND. The ALND in SLN+ patients was not significantly associated with 5-year breast cancer-specific survival (hazard ratio [HR] 1.22, 95 % confidence interval [CI] 0.76–1.96). The SLN+ patients who underwent ALND were more likely to receive adjuvant chemotherapy (odds ratio [OR] 1.8, 95 % CI 1.45–2.24). However, younger age (OR 18.0, 95 % CI 14.4–23.9), estrogen receptor-negative (ER-) status (OR 4.2, 95 % CI 3.4–5.3), and fewer comorbidities (OR 2.6, 95 % CI 1.7–4.0) were all more strongly linked to receipt of chemotherapy.
ALND for older patients with SLN+ breast cancer is not associated with improved 5-year all-cause or breast cancer-specific survival. Younger age, fewer comorbidities, and estrogen receptor-negative (ER-) status were more strongly associated with receipt of chemotherapy than ALND. Consideration should be given to omitting ALND in older patients, particularly if findings of ALND will not influence adjuvant therapy decisions.
- MMWR. From the Centers for Disease Control and Prevention Public Health and aging: trends in aging—United States and worldwide. JAMA. 2003;289:1371–3. CrossRef
- Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7. CrossRef
- Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer–a multicenter validation study. N Engl J Med. 1998;339:941–6. CrossRef
- Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394–9. CrossRef
- Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–53. CrossRef
- Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13:491–500. CrossRef
- Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75. CrossRef
- Karam AK, Hsu M, Patil S, et al. Predictors of completion axillary lymph node dissection in patients with positive sentinel lymph nodes. Ann Surg Oncol. 2009;16:1952–8. CrossRef
- Truong PT, Bernstein V, Wai E, et al. Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1-T2 breast cancer. Int J Radiat Oncol Biol Phys. 2002;54:794–803. CrossRef
- Aziz D, Gardner S, Pritchard K, et al. Selective application of axillary node dissection in elderly women with early breast cancer. Ann Surg Oncol. 2007;14:652–9. CrossRef
- Reeder-Hayes KE, Bainbridge J, Meyer AM, et al. Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer. Breast Cancer Res Treat. 2011;128:863–71. CrossRef
- Rescigno J, Zampell JC, Axelrod D. Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy. Ann Surg Oncol. 2009;16:687–96. CrossRef
- Maggard MA, Lane KE, O’Connell JB, et al. Beyond the clinical trials: how often is sentinel lymph node dissection performed for breast cancer? Ann Surg Oncol. 2005;12:41–7. CrossRef
- Chen AY, Halpern MT, Schrag NM, et al. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998–2005). J Natl Cancer Inst. 2008;100:462–74. CrossRef
- Halpern MT, Chen AY, Marlow NS, et al. Disparities in receipt of lymph node biopsy among early-stage female breast cancer patients. Ann Surg Oncol. 2009;16:562–70. CrossRef
- Edge SB, Gold K, Berg CD, et al. Patient and provider characteristics that affect the use of axillary dissection in older women with stage I-II breast carcinoma. Outcomes and Preferences for Treatment in Older Women Nationwide Study Research Team. Cancer. 2002;94:2534–41. CrossRef
- Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 Suppl):IV-3–18.
- Enger SM, Thwin SS, Buist DS, et al. Breast cancer treatment of older women in integrated health care settings. J Clin Oncol. 2006;24:4377–83. CrossRef
- Ballard-Barbash R, Potosky AL, Harlan LC, et al. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst. 1996;88:716–26. CrossRef
- Silliman RA, Troyan SL, Guadagnoli E, et al. The impact of age, marital status, and physician-patient interactions on the care of older women with breast cancer. Cancer. 1997;80:1326–34. CrossRef
- Hebert-Croteau N, Brisson J, Latreille J, et al. Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer. 1999;85:104–13. CrossRef
- Mandelblatt JS, Hadley J, Kerner JF, et al. Patterns of breast carcinoma treatment in older women: Patient preference and clinical and physician influences. Cancer. 2000;89:561–73. CrossRef
- Martelli G, Boracchi P, Ardoino I, et al. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Ann Surg. 2012;256:920–4. CrossRef
- Näslund E, Fernstad R, Ekman S, et al. Breast cancer in women over 75 years: is axillary dissection always necessary? Eur J Surg. 1996;162:867–71.
- Dees EC, Shulman LN, Souba WW, et al: Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection. Ann Surg. 1997;226:279–86. CrossRef
- Feigelson BJ, Acosta JA, Feigelson HS, et al. T1 breast carcinoma in women 70 years of age and older may not require axillary lymph node dissection. Am J Surg. 1996;172:487–9. CrossRef
- Muss HB, Woolf S, Berry D, et al. Cancer and Leukemia Group B: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293:1073–81. CrossRef
- Commission on Cancer National Cancer Data Base (NCDB). Coding Cancer Registry Items. 2012. http://www.facs.org/cancer/ncdb/scope-regional-lymph-node-surgery.pdf. Accessed 1 Dec 2013.
- Predictors and Outcomes of Completion Axillary Node Dissection Among Older Breast Cancer Patients
Annals of Surgical Oncology
Volume 21, Issue 7 , pp 2172-2180
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Industry Sectors